Urologic Neoplasms Clinical Trial
Official title:
Antegrade Double-J Stent Placement for the Treatment of Malignant Obstructive Uropathy: a Single Center Experience
Ureteral double- J stent is usually inserted by retrograde approach for the treatment of obstructed upper urinary tract. The antegrade approach, can a suitable alternative in certain situations without the need for general or spinal anesthesia. The present study demonstrates the indications, success rate, and complications of this approach in the treatment of malignant obstructive uropathy.
Data of consecutive patients in whom antegrade ureteral stent¬ing was performed between January 2013 and February 2020 were retrospectively analysed using patient records and radiology reports. A total of 174 patients (sexe ratio = 0.51, age range 9-91 years; mean age, 54 years) were included in the study. Ureteral obstruction was caused by bladder cancer (n=92), uterin cancer (n=31), prostate cancer (n=28), colorectal cancer (n= 15) and retroperitoneal tumor (n= 8) (Table 1). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00151034 -
Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer
|
Phase 2 | |
Completed |
NCT04933604 -
LPN in Patients With High-complex Renal Tumors
|
||
Completed |
NCT03219333 -
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
|
Phase 2 | |
Completed |
NCT04052113 -
Real World Evidence of PD-L1, TMB Prevalence and Efficacy of 1st Line Chemotherapy in These High or Low Population for Stage IV Urothelial Cancer
|
||
Terminated |
NCT02543645 -
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT01454089 -
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03288545 -
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05025930 -
Evaluate the Safety and Effectiveness of the Endoscopic Surgical Instrument Control System (SP1000).
|
N/A | |
Not yet recruiting |
NCT05135520 -
Transvaginal Versus Transabdominal Extraction of Laparoscopically-excised Kidney Specimen
|
N/A | |
Withdrawn |
NCT04630483 -
Platelet-lymphocyte and Neutrophil-lymphocyte Ratio in Patients Undergoing Cancer Surgery
|
||
Terminated |
NCT02386111 -
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
|
Phase 1 | |
Completed |
NCT03081858 -
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04644432 -
Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT05308771 -
To Investigate the Use of a New Syringe "Visual Pressure Control (VPC)" for Epidural Anesthesia in Children Surgery
|
N/A | |
Terminated |
NCT00226954 -
Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
|
Phase 2 | |
Completed |
NCT05113134 -
Transvaginal Versus Transabdominal Extraction of Laparoscopically-excised Specimen
|
N/A | |
Completed |
NCT04213157 -
Laparoscopic Partial Nephrectomy for cT1 Tumors
|
||
Completed |
NCT02780687 -
Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy
|
Phase 2 | |
Recruiting |
NCT04922047 -
Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06353906 -
Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
|
Phase 2 |